These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 3512944)
1. Physostigmine effects in Alzheimer's disease: relationship to dementia severity. Schwartz AS; Kohlstaedt EV Life Sci; 1986 Mar; 38(11):1021-8. PubMed ID: 3512944 [TBL] [Abstract][Full Text] [Related]
2. Effects of oral physostigmine in Alzheimer's disease. Stern Y; Sano M; Mayeux R Ann Neurol; 1987 Sep; 22(3):306-10. PubMed ID: 3674795 [TBL] [Abstract][Full Text] [Related]
3. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial. Jenike MA; Albert MS; Heller H; Gunther J; Goff D J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level. Beller SA; Overall JE; Swann AC Psychopharmacology (Berl); 1985; 87(2):147-51. PubMed ID: 3931138 [TBL] [Abstract][Full Text] [Related]
5. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Davis KL; Mohs RC Am J Psychiatry; 1982 Nov; 139(11):1421-4. PubMed ID: 6753611 [TBL] [Abstract][Full Text] [Related]
6. Biological and neuropsychological characterization of physostigmine responders and nonresponders in Alzheimer's disease. Harrell LE; Jope RS; Falgout J; Callaway R; Avery C; Spiers M; Leli D; Morere D; Halsey JH J Am Geriatr Soc; 1990 Feb; 38(2):113-22. PubMed ID: 2405043 [TBL] [Abstract][Full Text] [Related]
7. Oral physostigmine and lecithin improve memory in Alzheimer disease. Thal LJ; Fuld PA; Masur DM; Sharpless NS Ann Neurol; 1983 May; 13(5):491-6. PubMed ID: 6347034 [TBL] [Abstract][Full Text] [Related]
8. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Christie JE; Shering A; Ferguson J; Glen AI Br J Psychiatry; 1981 Jan; 138():46-50. PubMed ID: 7023592 [TBL] [Abstract][Full Text] [Related]
9. Improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the Alzheimer type. Sevush S; Guterman A; Villalon AV J Clin Psychiatry; 1991 Jul; 52(7):300-3. PubMed ID: 2071560 [TBL] [Abstract][Full Text] [Related]
10. Long-term administration of oral physostigmine in Alzheimer's disease. Stern Y; Sano M; Mayeux R Neurology; 1988 Dec; 38(12):1837-41. PubMed ID: 3057398 [TBL] [Abstract][Full Text] [Related]
12. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease. Wettstein A Ann Neurol; 1983 Feb; 13(2):210-2. PubMed ID: 6830183 [TBL] [Abstract][Full Text] [Related]
13. Oral physostigmine treatment of patients with Alzheimer's disease. Mohs RC; Davis BM; Johns CA; Mathé AA; Greenwald BS; Horvath TB; Davis KL Am J Psychiatry; 1985 Jan; 142(1):28-33. PubMed ID: 3881051 [TBL] [Abstract][Full Text] [Related]
14. Clinical studies of the cholinergic deficit in Alzheimer's disease. II. Psychopharmacologic studies. Mohs RC; Davis BM; Greenwald BS; Mathé AA; Johns CA; Horvath TB; Davis KL J Am Geriatr Soc; 1985 Nov; 33(11):749-57. PubMed ID: 2865282 [TBL] [Abstract][Full Text] [Related]
16. Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer type. Möller H-J ; Hampel H; Hegerl U; Schmitt W; Walter K Pharmacopsychiatry; 1999 May; 32(3):99-106. PubMed ID: 10463377 [TBL] [Abstract][Full Text] [Related]
17. Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease. Thal LJ; Masur DM; Sharpless NS; Fuld PA; Davies P Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):627-36. PubMed ID: 3797688 [TBL] [Abstract][Full Text] [Related]
18. Memory enhancement with oral physostigmine in Alzheimer's disease. N Engl J Med; 1983 Mar; 308(12):720-1. PubMed ID: 6338388 [No Abstract] [Full Text] [Related]